nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—ORM1—Erlotinib—pancreatic cancer	0.0675	0.115	CbGbCtD
Tacrolimus—CYP3A7—Tamoxifen—pancreatic cancer	0.0358	0.0612	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Tamoxifen—pancreatic cancer	0.0358	0.0612	CbGbCtD
Tacrolimus—ALB—Erlotinib—pancreatic cancer	0.0284	0.0486	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Irinotecan—pancreatic cancer	0.0275	0.047	CbGbCtD
Tacrolimus—CYP3A7—Irinotecan—pancreatic cancer	0.0275	0.047	CbGbCtD
Tacrolimus—CYP3A5—Tamoxifen—pancreatic cancer	0.0268	0.0459	CbGbCtD
Tacrolimus—ALB—Irinotecan—pancreatic cancer	0.0256	0.0439	CbGbCtD
Tacrolimus—ALB—Fluorouracil—pancreatic cancer	0.0246	0.0421	CbGbCtD
Tacrolimus—CYP3A5—Erlotinib—pancreatic cancer	0.0228	0.039	CbGbCtD
Tacrolimus—CYP3A5—Irinotecan—pancreatic cancer	0.0206	0.0353	CbGbCtD
Tacrolimus—CYP3A7—Docetaxel—pancreatic cancer	0.0201	0.0344	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Docetaxel—pancreatic cancer	0.0201	0.0344	CbGbCtD
Tacrolimus—CYP3A7-CYP3A51P—Sunitinib—pancreatic cancer	0.02	0.0343	CbGbCtD
Tacrolimus—CYP3A7—Sunitinib—pancreatic cancer	0.02	0.0343	CbGbCtD
Tacrolimus—ABCB1—Tamoxifen—pancreatic cancer	0.0175	0.0299	CbGbCtD
Tacrolimus—CYP3A5—Docetaxel—pancreatic cancer	0.0151	0.0258	CbGbCtD
Tacrolimus—ABCB1—Gemcitabine—pancreatic cancer	0.015	0.0257	CbGbCtD
Tacrolimus—CYP3A5—Sunitinib—pancreatic cancer	0.015	0.0257	CbGbCtD
Tacrolimus—ABCB1—Erlotinib—pancreatic cancer	0.0148	0.0254	CbGbCtD
Tacrolimus—ABCB1—Irinotecan—pancreatic cancer	0.0134	0.0229	CbGbCtD
Tacrolimus—CYP3A4—Tamoxifen—pancreatic cancer	0.0105	0.0179	CbGbCtD
Tacrolimus—ABCB1—Docetaxel—pancreatic cancer	0.00983	0.0168	CbGbCtD
Tacrolimus—ABCB1—Sunitinib—pancreatic cancer	0.00978	0.0167	CbGbCtD
Tacrolimus—CYP3A4—Erlotinib—pancreatic cancer	0.0089	0.0152	CbGbCtD
Tacrolimus—ORM1—bile—pancreatic cancer	0.0082	0.235	CbGeAlD
Tacrolimus—CYP3A4—Irinotecan—pancreatic cancer	0.00803	0.0137	CbGbCtD
Tacrolimus—ABCB1—Doxorubicin—pancreatic cancer	0.00733	0.0125	CbGbCtD
Tacrolimus—CYP3A4—Docetaxel—pancreatic cancer	0.00589	0.0101	CbGbCtD
Tacrolimus—CYP3A4—Sunitinib—pancreatic cancer	0.00586	0.01	CbGbCtD
Tacrolimus—CYP3A4—Doxorubicin—pancreatic cancer	0.00439	0.00751	CbGbCtD
Tacrolimus—ABCA5—islet of Langerhans—pancreatic cancer	0.00425	0.122	CbGeAlD
Tacrolimus—ABCA5—pancreas—pancreatic cancer	0.00298	0.0856	CbGeAlD
Tacrolimus—PPP3CA—islet of Langerhans—pancreatic cancer	0.00287	0.0823	CbGeAlD
Tacrolimus—ORM1—gall bladder—pancreatic cancer	0.00228	0.0653	CbGeAlD
Tacrolimus—PPP3CA—pancreas—pancreatic cancer	0.00202	0.0579	CbGeAlD
Tacrolimus—ALB—gall bladder—pancreatic cancer	0.002	0.0573	CbGeAlD
Tacrolimus—PPP3CA—digestive system—pancreatic cancer	0.00172	0.0494	CbGeAlD
Tacrolimus—MTOR—pancreas—pancreatic cancer	0.00149	0.0427	CbGeAlD
Tacrolimus—FKBP1A—pancreas—pancreatic cancer	0.00134	0.0384	CbGeAlD
Tacrolimus—MTOR—digestive system—pancreatic cancer	0.00127	0.0365	CbGeAlD
Tacrolimus—FKBP1A—digestive system—pancreatic cancer	0.00114	0.0328	CbGeAlD
Tacrolimus—CYP3A5—islet of Langerhans—pancreatic cancer	0.00083	0.0238	CbGeAlD
Tacrolimus—CYP3A5—pancreas—pancreatic cancer	0.000583	0.0167	CbGeAlD
Tacrolimus—CYP3A5—digestive system—pancreatic cancer	0.000498	0.0143	CbGeAlD
Tacrolimus—ABCB1—islet of Langerhans—pancreatic cancer	0.000441	0.0126	CbGeAlD
Tacrolimus—CYP3A4—digestive system—pancreatic cancer	0.000374	0.0107	CbGeAlD
Tacrolimus—ABCB1—pancreas—pancreatic cancer	0.00031	0.00889	CbGeAlD
Tacrolimus—ABCB1—digestive system—pancreatic cancer	0.000265	0.00759	CbGeAlD
Tacrolimus—Diarrhoea—Irinotecan—pancreatic cancer	5.82e-05	0.000226	CcSEcCtD
Tacrolimus—Agranulocytosis—Epirubicin—pancreatic cancer	5.81e-05	0.000225	CcSEcCtD
Tacrolimus—Pneumonia—Doxorubicin—pancreatic cancer	5.79e-05	0.000225	CcSEcCtD
Tacrolimus—Shock—Docetaxel—pancreatic cancer	5.79e-05	0.000225	CcSEcCtD
Tacrolimus—Nervous system disorder—Docetaxel—pancreatic cancer	5.77e-05	0.000224	CcSEcCtD
Tacrolimus—Pruritus—Fluorouracil—pancreatic cancer	5.77e-05	0.000224	CcSEcCtD
Tacrolimus—Thrombocytopenia—Docetaxel—pancreatic cancer	5.76e-05	0.000224	CcSEcCtD
Tacrolimus—Infestation NOS—Doxorubicin—pancreatic cancer	5.76e-05	0.000223	CcSEcCtD
Tacrolimus—Infestation—Doxorubicin—pancreatic cancer	5.76e-05	0.000223	CcSEcCtD
Tacrolimus—Tachycardia—Docetaxel—pancreatic cancer	5.74e-05	0.000223	CcSEcCtD
Tacrolimus—Skin disorder—Docetaxel—pancreatic cancer	5.72e-05	0.000222	CcSEcCtD
Tacrolimus—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	5.71e-05	0.000221	CcSEcCtD
Tacrolimus—Bradycardia—Epirubicin—pancreatic cancer	5.69e-05	0.000221	CcSEcCtD
Tacrolimus—Diarrhoea—Gemcitabine—pancreatic cancer	5.67e-05	0.00022	CcSEcCtD
Tacrolimus—Renal failure—Doxorubicin—pancreatic cancer	5.66e-05	0.00022	CcSEcCtD
Tacrolimus—Neuropathy peripheral—Doxorubicin—pancreatic cancer	5.64e-05	0.000219	CcSEcCtD
Tacrolimus—Dizziness—Irinotecan—pancreatic cancer	5.63e-05	0.000218	CcSEcCtD
Tacrolimus—Haemoglobin—Epirubicin—pancreatic cancer	5.62e-05	0.000218	CcSEcCtD
Tacrolimus—Stomatitis—Doxorubicin—pancreatic cancer	5.61e-05	0.000218	CcSEcCtD
Tacrolimus—Jaundice—Doxorubicin—pancreatic cancer	5.61e-05	0.000218	CcSEcCtD
Tacrolimus—Anorexia—Docetaxel—pancreatic cancer	5.61e-05	0.000218	CcSEcCtD
Tacrolimus—Rhinitis—Epirubicin—pancreatic cancer	5.6e-05	0.000217	CcSEcCtD
Tacrolimus—Conjunctivitis—Doxorubicin—pancreatic cancer	5.6e-05	0.000217	CcSEcCtD
Tacrolimus—Urinary tract infection—Doxorubicin—pancreatic cancer	5.6e-05	0.000217	CcSEcCtD
Tacrolimus—Hepatitis—Epirubicin—pancreatic cancer	5.59e-05	0.000217	CcSEcCtD
Tacrolimus—Haemorrhage—Epirubicin—pancreatic cancer	5.59e-05	0.000217	CcSEcCtD
Tacrolimus—Diarrhoea—Fluorouracil—pancreatic cancer	5.58e-05	0.000216	CcSEcCtD
Tacrolimus—Hypoaesthesia—Epirubicin—pancreatic cancer	5.56e-05	0.000216	CcSEcCtD
Tacrolimus—Pharyngitis—Epirubicin—pancreatic cancer	5.55e-05	0.000215	CcSEcCtD
Tacrolimus—Sweating—Doxorubicin—pancreatic cancer	5.52e-05	0.000214	CcSEcCtD
Tacrolimus—Urinary tract disorder—Epirubicin—pancreatic cancer	5.52e-05	0.000214	CcSEcCtD
Tacrolimus—Oedema peripheral—Epirubicin—pancreatic cancer	5.5e-05	0.000214	CcSEcCtD
Tacrolimus—Hypotension—Docetaxel—pancreatic cancer	5.5e-05	0.000213	CcSEcCtD
Tacrolimus—Haematuria—Doxorubicin—pancreatic cancer	5.49e-05	0.000213	CcSEcCtD
Tacrolimus—Connective tissue disorder—Epirubicin—pancreatic cancer	5.49e-05	0.000213	CcSEcCtD
Tacrolimus—Urethral disorder—Epirubicin—pancreatic cancer	5.48e-05	0.000212	CcSEcCtD
Tacrolimus—Hepatobiliary disease—Doxorubicin—pancreatic cancer	5.45e-05	0.000211	CcSEcCtD
Tacrolimus—Epistaxis—Doxorubicin—pancreatic cancer	5.43e-05	0.000211	CcSEcCtD
Tacrolimus—Vomiting—Irinotecan—pancreatic cancer	5.41e-05	0.00021	CcSEcCtD
Tacrolimus—Sinusitis—Doxorubicin—pancreatic cancer	5.4e-05	0.00021	CcSEcCtD
Tacrolimus—Dizziness—Fluorouracil—pancreatic cancer	5.39e-05	0.000209	CcSEcCtD
Tacrolimus—Visual impairment—Epirubicin—pancreatic cancer	5.38e-05	0.000209	CcSEcCtD
Tacrolimus—Agranulocytosis—Doxorubicin—pancreatic cancer	5.37e-05	0.000208	CcSEcCtD
Tacrolimus—Rash—Irinotecan—pancreatic cancer	5.37e-05	0.000208	CcSEcCtD
Tacrolimus—Dermatitis—Irinotecan—pancreatic cancer	5.36e-05	0.000208	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	5.36e-05	0.000208	CcSEcCtD
Tacrolimus—Headache—Irinotecan—pancreatic cancer	5.33e-05	0.000207	CcSEcCtD
Tacrolimus—Insomnia—Docetaxel—pancreatic cancer	5.32e-05	0.000207	CcSEcCtD
Tacrolimus—Paraesthesia—Docetaxel—pancreatic cancer	5.28e-05	0.000205	CcSEcCtD
Tacrolimus—Erythema multiforme—Epirubicin—pancreatic cancer	5.28e-05	0.000205	CcSEcCtD
Tacrolimus—Vomiting—Gemcitabine—pancreatic cancer	5.27e-05	0.000205	CcSEcCtD
Tacrolimus—Bradycardia—Doxorubicin—pancreatic cancer	5.26e-05	0.000204	CcSEcCtD
Tacrolimus—Dyspnoea—Docetaxel—pancreatic cancer	5.25e-05	0.000204	CcSEcCtD
Tacrolimus—Somnolence—Docetaxel—pancreatic cancer	5.23e-05	0.000203	CcSEcCtD
Tacrolimus—Rash—Gemcitabine—pancreatic cancer	5.23e-05	0.000203	CcSEcCtD
Tacrolimus—Dermatitis—Gemcitabine—pancreatic cancer	5.22e-05	0.000203	CcSEcCtD
Tacrolimus—Eye disorder—Epirubicin—pancreatic cancer	5.22e-05	0.000203	CcSEcCtD
Tacrolimus—Tinnitus—Epirubicin—pancreatic cancer	5.21e-05	0.000202	CcSEcCtD
Tacrolimus—Haemoglobin—Doxorubicin—pancreatic cancer	5.2e-05	0.000202	CcSEcCtD
Tacrolimus—Headache—Gemcitabine—pancreatic cancer	5.2e-05	0.000202	CcSEcCtD
Tacrolimus—Cardiac disorder—Epirubicin—pancreatic cancer	5.19e-05	0.000201	CcSEcCtD
Tacrolimus—Flushing—Epirubicin—pancreatic cancer	5.19e-05	0.000201	CcSEcCtD
Tacrolimus—Vomiting—Fluorouracil—pancreatic cancer	5.18e-05	0.000201	CcSEcCtD
Tacrolimus—Rhinitis—Doxorubicin—pancreatic cancer	5.18e-05	0.000201	CcSEcCtD
Tacrolimus—Dyspepsia—Docetaxel—pancreatic cancer	5.18e-05	0.000201	CcSEcCtD
Tacrolimus—Hepatitis—Doxorubicin—pancreatic cancer	5.17e-05	0.000201	CcSEcCtD
Tacrolimus—Haemorrhage—Doxorubicin—pancreatic cancer	5.17e-05	0.000201	CcSEcCtD
Tacrolimus—Hypoaesthesia—Doxorubicin—pancreatic cancer	5.14e-05	0.0002	CcSEcCtD
Tacrolimus—Rash—Fluorouracil—pancreatic cancer	5.14e-05	0.000199	CcSEcCtD
Tacrolimus—Dermatitis—Fluorouracil—pancreatic cancer	5.14e-05	0.000199	CcSEcCtD
Tacrolimus—Pharyngitis—Doxorubicin—pancreatic cancer	5.13e-05	0.000199	CcSEcCtD
Tacrolimus—Decreased appetite—Docetaxel—pancreatic cancer	5.12e-05	0.000198	CcSEcCtD
Tacrolimus—Headache—Fluorouracil—pancreatic cancer	5.11e-05	0.000198	CcSEcCtD
Tacrolimus—Urinary tract disorder—Doxorubicin—pancreatic cancer	5.11e-05	0.000198	CcSEcCtD
Tacrolimus—Oedema peripheral—Doxorubicin—pancreatic cancer	5.09e-05	0.000198	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Docetaxel—pancreatic cancer	5.08e-05	0.000197	CcSEcCtD
Tacrolimus—Connective tissue disorder—Doxorubicin—pancreatic cancer	5.08e-05	0.000197	CcSEcCtD
Tacrolimus—Fatigue—Docetaxel—pancreatic cancer	5.07e-05	0.000197	CcSEcCtD
Tacrolimus—Angiopathy—Epirubicin—pancreatic cancer	5.07e-05	0.000197	CcSEcCtD
Tacrolimus—Urethral disorder—Doxorubicin—pancreatic cancer	5.07e-05	0.000197	CcSEcCtD
Tacrolimus—Nausea—Irinotecan—pancreatic cancer	5.06e-05	0.000196	CcSEcCtD
Tacrolimus—Immune system disorder—Epirubicin—pancreatic cancer	5.05e-05	0.000196	CcSEcCtD
Tacrolimus—Mediastinal disorder—Epirubicin—pancreatic cancer	5.04e-05	0.000195	CcSEcCtD
Tacrolimus—Pain—Docetaxel—pancreatic cancer	5.03e-05	0.000195	CcSEcCtD
Tacrolimus—Constipation—Docetaxel—pancreatic cancer	5.03e-05	0.000195	CcSEcCtD
Tacrolimus—Chills—Epirubicin—pancreatic cancer	5.01e-05	0.000194	CcSEcCtD
Tacrolimus—Arrhythmia—Epirubicin—pancreatic cancer	4.99e-05	0.000194	CcSEcCtD
Tacrolimus—Visual impairment—Doxorubicin—pancreatic cancer	4.98e-05	0.000193	CcSEcCtD
Tacrolimus—Alopecia—Epirubicin—pancreatic cancer	4.94e-05	0.000192	CcSEcCtD
Tacrolimus—Nausea—Gemcitabine—pancreatic cancer	4.93e-05	0.000191	CcSEcCtD
Tacrolimus—Mental disorder—Epirubicin—pancreatic cancer	4.89e-05	0.00019	CcSEcCtD
Tacrolimus—Erythema multiforme—Doxorubicin—pancreatic cancer	4.89e-05	0.00019	CcSEcCtD
Tacrolimus—Erythema—Epirubicin—pancreatic cancer	4.86e-05	0.000189	CcSEcCtD
Tacrolimus—Malnutrition—Epirubicin—pancreatic cancer	4.86e-05	0.000189	CcSEcCtD
Tacrolimus—Feeling abnormal—Docetaxel—pancreatic cancer	4.85e-05	0.000188	CcSEcCtD
Tacrolimus—Nausea—Fluorouracil—pancreatic cancer	4.84e-05	0.000188	CcSEcCtD
Tacrolimus—Eye disorder—Doxorubicin—pancreatic cancer	4.83e-05	0.000187	CcSEcCtD
Tacrolimus—Tinnitus—Doxorubicin—pancreatic cancer	4.82e-05	0.000187	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Docetaxel—pancreatic cancer	4.81e-05	0.000187	CcSEcCtD
Tacrolimus—Cardiac disorder—Doxorubicin—pancreatic cancer	4.8e-05	0.000186	CcSEcCtD
Tacrolimus—Flushing—Doxorubicin—pancreatic cancer	4.8e-05	0.000186	CcSEcCtD
Tacrolimus—Flatulence—Epirubicin—pancreatic cancer	4.79e-05	0.000186	CcSEcCtD
Tacrolimus—Tension—Epirubicin—pancreatic cancer	4.77e-05	0.000185	CcSEcCtD
Tacrolimus—Dysgeusia—Epirubicin—pancreatic cancer	4.76e-05	0.000185	CcSEcCtD
Tacrolimus—Nervousness—Epirubicin—pancreatic cancer	4.72e-05	0.000183	CcSEcCtD
Tacrolimus—Back pain—Epirubicin—pancreatic cancer	4.7e-05	0.000183	CcSEcCtD
Tacrolimus—Angiopathy—Doxorubicin—pancreatic cancer	4.69e-05	0.000182	CcSEcCtD
Tacrolimus—Muscle spasms—Epirubicin—pancreatic cancer	4.68e-05	0.000181	CcSEcCtD
Tacrolimus—Immune system disorder—Doxorubicin—pancreatic cancer	4.67e-05	0.000181	CcSEcCtD
Tacrolimus—Mediastinal disorder—Doxorubicin—pancreatic cancer	4.66e-05	0.000181	CcSEcCtD
Tacrolimus—Abdominal pain—Docetaxel—pancreatic cancer	4.65e-05	0.00018	CcSEcCtD
Tacrolimus—Body temperature increased—Docetaxel—pancreatic cancer	4.65e-05	0.00018	CcSEcCtD
Tacrolimus—Chills—Doxorubicin—pancreatic cancer	4.64e-05	0.00018	CcSEcCtD
Tacrolimus—Arrhythmia—Doxorubicin—pancreatic cancer	4.62e-05	0.000179	CcSEcCtD
Tacrolimus—Vision blurred—Epirubicin—pancreatic cancer	4.58e-05	0.000178	CcSEcCtD
Tacrolimus—Alopecia—Doxorubicin—pancreatic cancer	4.57e-05	0.000177	CcSEcCtD
Tacrolimus—Mental disorder—Doxorubicin—pancreatic cancer	4.53e-05	0.000176	CcSEcCtD
Tacrolimus—Ill-defined disorder—Epirubicin—pancreatic cancer	4.51e-05	0.000175	CcSEcCtD
Tacrolimus—Erythema—Doxorubicin—pancreatic cancer	4.5e-05	0.000175	CcSEcCtD
Tacrolimus—Malnutrition—Doxorubicin—pancreatic cancer	4.5e-05	0.000175	CcSEcCtD
Tacrolimus—Anaemia—Epirubicin—pancreatic cancer	4.5e-05	0.000174	CcSEcCtD
Tacrolimus—Agitation—Epirubicin—pancreatic cancer	4.47e-05	0.000173	CcSEcCtD
Tacrolimus—Flatulence—Doxorubicin—pancreatic cancer	4.43e-05	0.000172	CcSEcCtD
Tacrolimus—Tension—Doxorubicin—pancreatic cancer	4.42e-05	0.000171	CcSEcCtD
Tacrolimus—Dysgeusia—Doxorubicin—pancreatic cancer	4.41e-05	0.000171	CcSEcCtD
Tacrolimus—Malaise—Epirubicin—pancreatic cancer	4.39e-05	0.00017	CcSEcCtD
Tacrolimus—Nervousness—Doxorubicin—pancreatic cancer	4.37e-05	0.00017	CcSEcCtD
Tacrolimus—Vertigo—Epirubicin—pancreatic cancer	4.37e-05	0.00017	CcSEcCtD
Tacrolimus—Syncope—Epirubicin—pancreatic cancer	4.36e-05	0.000169	CcSEcCtD
Tacrolimus—Leukopenia—Epirubicin—pancreatic cancer	4.35e-05	0.000169	CcSEcCtD
Tacrolimus—Back pain—Doxorubicin—pancreatic cancer	4.35e-05	0.000169	CcSEcCtD
Tacrolimus—Hypersensitivity—Docetaxel—pancreatic cancer	4.34e-05	0.000168	CcSEcCtD
Tacrolimus—Muscle spasms—Doxorubicin—pancreatic cancer	4.33e-05	0.000168	CcSEcCtD
Tacrolimus—Palpitations—Epirubicin—pancreatic cancer	4.3e-05	0.000167	CcSEcCtD
Tacrolimus—Loss of consciousness—Epirubicin—pancreatic cancer	4.27e-05	0.000166	CcSEcCtD
Tacrolimus—Cough—Epirubicin—pancreatic cancer	4.24e-05	0.000165	CcSEcCtD
Tacrolimus—Vision blurred—Doxorubicin—pancreatic cancer	4.24e-05	0.000165	CcSEcCtD
Tacrolimus—Asthenia—Docetaxel—pancreatic cancer	4.22e-05	0.000164	CcSEcCtD
Tacrolimus—Convulsion—Epirubicin—pancreatic cancer	4.21e-05	0.000163	CcSEcCtD
Tacrolimus—Hypertension—Epirubicin—pancreatic cancer	4.2e-05	0.000163	CcSEcCtD
Tacrolimus—Ill-defined disorder—Doxorubicin—pancreatic cancer	4.18e-05	0.000162	CcSEcCtD
Tacrolimus—Pruritus—Docetaxel—pancreatic cancer	4.16e-05	0.000162	CcSEcCtD
Tacrolimus—Anaemia—Doxorubicin—pancreatic cancer	4.16e-05	0.000161	CcSEcCtD
Tacrolimus—Chest pain—Epirubicin—pancreatic cancer	4.14e-05	0.000161	CcSEcCtD
Tacrolimus—Myalgia—Epirubicin—pancreatic cancer	4.14e-05	0.000161	CcSEcCtD
Tacrolimus—Arthralgia—Epirubicin—pancreatic cancer	4.14e-05	0.000161	CcSEcCtD
Tacrolimus—Agitation—Doxorubicin—pancreatic cancer	4.14e-05	0.00016	CcSEcCtD
Tacrolimus—Anxiety—Epirubicin—pancreatic cancer	4.13e-05	0.00016	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	4.11e-05	0.00016	CcSEcCtD
Tacrolimus—Discomfort—Epirubicin—pancreatic cancer	4.09e-05	0.000159	CcSEcCtD
Tacrolimus—Malaise—Doxorubicin—pancreatic cancer	4.06e-05	0.000157	CcSEcCtD
Tacrolimus—Dry mouth—Epirubicin—pancreatic cancer	4.05e-05	0.000157	CcSEcCtD
Tacrolimus—Vertigo—Doxorubicin—pancreatic cancer	4.04e-05	0.000157	CcSEcCtD
Tacrolimus—Syncope—Doxorubicin—pancreatic cancer	4.04e-05	0.000157	CcSEcCtD
Tacrolimus—Leukopenia—Doxorubicin—pancreatic cancer	4.03e-05	0.000156	CcSEcCtD
Tacrolimus—Diarrhoea—Docetaxel—pancreatic cancer	4.03e-05	0.000156	CcSEcCtD
Tacrolimus—Confusional state—Epirubicin—pancreatic cancer	4e-05	0.000155	CcSEcCtD
Tacrolimus—Palpitations—Doxorubicin—pancreatic cancer	3.98e-05	0.000154	CcSEcCtD
Tacrolimus—Anaphylactic shock—Epirubicin—pancreatic cancer	3.97e-05	0.000154	CcSEcCtD
Tacrolimus—Oedema—Epirubicin—pancreatic cancer	3.97e-05	0.000154	CcSEcCtD
Tacrolimus—Loss of consciousness—Doxorubicin—pancreatic cancer	3.96e-05	0.000153	CcSEcCtD
Tacrolimus—Infection—Epirubicin—pancreatic cancer	3.94e-05	0.000153	CcSEcCtD
Tacrolimus—Cough—Doxorubicin—pancreatic cancer	3.93e-05	0.000152	CcSEcCtD
Tacrolimus—Shock—Epirubicin—pancreatic cancer	3.91e-05	0.000152	CcSEcCtD
Tacrolimus—Convulsion—Doxorubicin—pancreatic cancer	3.9e-05	0.000151	CcSEcCtD
Tacrolimus—Nervous system disorder—Epirubicin—pancreatic cancer	3.89e-05	0.000151	CcSEcCtD
Tacrolimus—Dizziness—Docetaxel—pancreatic cancer	3.89e-05	0.000151	CcSEcCtD
Tacrolimus—Thrombocytopenia—Epirubicin—pancreatic cancer	3.89e-05	0.000151	CcSEcCtD
Tacrolimus—Hypertension—Doxorubicin—pancreatic cancer	3.89e-05	0.000151	CcSEcCtD
Tacrolimus—Tachycardia—Epirubicin—pancreatic cancer	3.87e-05	0.00015	CcSEcCtD
Tacrolimus—Skin disorder—Epirubicin—pancreatic cancer	3.86e-05	0.00015	CcSEcCtD
Tacrolimus—Hyperhidrosis—Epirubicin—pancreatic cancer	3.84e-05	0.000149	CcSEcCtD
Tacrolimus—Chest pain—Doxorubicin—pancreatic cancer	3.83e-05	0.000149	CcSEcCtD
Tacrolimus—Myalgia—Doxorubicin—pancreatic cancer	3.83e-05	0.000149	CcSEcCtD
Tacrolimus—Arthralgia—Doxorubicin—pancreatic cancer	3.83e-05	0.000149	CcSEcCtD
Tacrolimus—Anxiety—Doxorubicin—pancreatic cancer	3.82e-05	0.000148	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	3.8e-05	0.000148	CcSEcCtD
Tacrolimus—Discomfort—Doxorubicin—pancreatic cancer	3.79e-05	0.000147	CcSEcCtD
Tacrolimus—Anorexia—Epirubicin—pancreatic cancer	3.78e-05	0.000147	CcSEcCtD
Tacrolimus—Dry mouth—Doxorubicin—pancreatic cancer	3.75e-05	0.000145	CcSEcCtD
Tacrolimus—Vomiting—Docetaxel—pancreatic cancer	3.74e-05	0.000145	CcSEcCtD
Tacrolimus—Rash—Docetaxel—pancreatic cancer	3.71e-05	0.000144	CcSEcCtD
Tacrolimus—Hypotension—Epirubicin—pancreatic cancer	3.71e-05	0.000144	CcSEcCtD
Tacrolimus—Dermatitis—Docetaxel—pancreatic cancer	3.71e-05	0.000144	CcSEcCtD
Tacrolimus—Confusional state—Doxorubicin—pancreatic cancer	3.7e-05	0.000144	CcSEcCtD
Tacrolimus—Headache—Docetaxel—pancreatic cancer	3.69e-05	0.000143	CcSEcCtD
Tacrolimus—Anaphylactic shock—Doxorubicin—pancreatic cancer	3.67e-05	0.000142	CcSEcCtD
Tacrolimus—Oedema—Doxorubicin—pancreatic cancer	3.67e-05	0.000142	CcSEcCtD
Tacrolimus—Infection—Doxorubicin—pancreatic cancer	3.65e-05	0.000142	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	3.62e-05	0.00014	CcSEcCtD
Tacrolimus—Shock—Doxorubicin—pancreatic cancer	3.61e-05	0.00014	CcSEcCtD
Tacrolimus—Nervous system disorder—Doxorubicin—pancreatic cancer	3.6e-05	0.00014	CcSEcCtD
Tacrolimus—Thrombocytopenia—Doxorubicin—pancreatic cancer	3.6e-05	0.00014	CcSEcCtD
Tacrolimus—Insomnia—Epirubicin—pancreatic cancer	3.59e-05	0.000139	CcSEcCtD
Tacrolimus—Tachycardia—Doxorubicin—pancreatic cancer	3.58e-05	0.000139	CcSEcCtD
Tacrolimus—Skin disorder—Doxorubicin—pancreatic cancer	3.57e-05	0.000138	CcSEcCtD
Tacrolimus—Paraesthesia—Epirubicin—pancreatic cancer	3.56e-05	0.000138	CcSEcCtD
Tacrolimus—Hyperhidrosis—Doxorubicin—pancreatic cancer	3.55e-05	0.000138	CcSEcCtD
Tacrolimus—Dyspnoea—Epirubicin—pancreatic cancer	3.54e-05	0.000137	CcSEcCtD
Tacrolimus—Somnolence—Epirubicin—pancreatic cancer	3.53e-05	0.000137	CcSEcCtD
Tacrolimus—Anorexia—Doxorubicin—pancreatic cancer	3.5e-05	0.000136	CcSEcCtD
Tacrolimus—Nausea—Docetaxel—pancreatic cancer	3.5e-05	0.000136	CcSEcCtD
Tacrolimus—Dyspepsia—Epirubicin—pancreatic cancer	3.49e-05	0.000136	CcSEcCtD
Tacrolimus—Decreased appetite—Epirubicin—pancreatic cancer	3.45e-05	0.000134	CcSEcCtD
Tacrolimus—Hypotension—Doxorubicin—pancreatic cancer	3.43e-05	0.000133	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Epirubicin—pancreatic cancer	3.43e-05	0.000133	CcSEcCtD
Tacrolimus—Fatigue—Epirubicin—pancreatic cancer	3.42e-05	0.000133	CcSEcCtD
Tacrolimus—Constipation—Epirubicin—pancreatic cancer	3.39e-05	0.000132	CcSEcCtD
Tacrolimus—Pain—Epirubicin—pancreatic cancer	3.39e-05	0.000132	CcSEcCtD
Tacrolimus—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	3.35e-05	0.00013	CcSEcCtD
Tacrolimus—Insomnia—Doxorubicin—pancreatic cancer	3.32e-05	0.000129	CcSEcCtD
Tacrolimus—Paraesthesia—Doxorubicin—pancreatic cancer	3.3e-05	0.000128	CcSEcCtD
Tacrolimus—Dyspnoea—Doxorubicin—pancreatic cancer	3.27e-05	0.000127	CcSEcCtD
Tacrolimus—Feeling abnormal—Epirubicin—pancreatic cancer	3.27e-05	0.000127	CcSEcCtD
Tacrolimus—Somnolence—Doxorubicin—pancreatic cancer	3.27e-05	0.000127	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Epirubicin—pancreatic cancer	3.25e-05	0.000126	CcSEcCtD
Tacrolimus—Dyspepsia—Doxorubicin—pancreatic cancer	3.23e-05	0.000125	CcSEcCtD
Tacrolimus—Decreased appetite—Doxorubicin—pancreatic cancer	3.19e-05	0.000124	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	3.17e-05	0.000123	CcSEcCtD
Tacrolimus—Fatigue—Doxorubicin—pancreatic cancer	3.17e-05	0.000123	CcSEcCtD
Tacrolimus—Urticaria—Epirubicin—pancreatic cancer	3.15e-05	0.000122	CcSEcCtD
Tacrolimus—Pain—Doxorubicin—pancreatic cancer	3.14e-05	0.000122	CcSEcCtD
Tacrolimus—Constipation—Doxorubicin—pancreatic cancer	3.14e-05	0.000122	CcSEcCtD
Tacrolimus—Abdominal pain—Epirubicin—pancreatic cancer	3.14e-05	0.000122	CcSEcCtD
Tacrolimus—Body temperature increased—Epirubicin—pancreatic cancer	3.14e-05	0.000122	CcSEcCtD
Tacrolimus—Feeling abnormal—Doxorubicin—pancreatic cancer	3.03e-05	0.000117	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Doxorubicin—pancreatic cancer	3e-05	0.000117	CcSEcCtD
Tacrolimus—Hypersensitivity—Epirubicin—pancreatic cancer	2.92e-05	0.000113	CcSEcCtD
Tacrolimus—Urticaria—Doxorubicin—pancreatic cancer	2.92e-05	0.000113	CcSEcCtD
Tacrolimus—Abdominal pain—Doxorubicin—pancreatic cancer	2.9e-05	0.000113	CcSEcCtD
Tacrolimus—Body temperature increased—Doxorubicin—pancreatic cancer	2.9e-05	0.000113	CcSEcCtD
Tacrolimus—Asthenia—Epirubicin—pancreatic cancer	2.85e-05	0.00011	CcSEcCtD
Tacrolimus—Pruritus—Epirubicin—pancreatic cancer	2.81e-05	0.000109	CcSEcCtD
Tacrolimus—Diarrhoea—Epirubicin—pancreatic cancer	2.72e-05	0.000105	CcSEcCtD
Tacrolimus—Hypersensitivity—Doxorubicin—pancreatic cancer	2.71e-05	0.000105	CcSEcCtD
Tacrolimus—Asthenia—Doxorubicin—pancreatic cancer	2.64e-05	0.000102	CcSEcCtD
Tacrolimus—Dizziness—Epirubicin—pancreatic cancer	2.62e-05	0.000102	CcSEcCtD
Tacrolimus—Pruritus—Doxorubicin—pancreatic cancer	2.6e-05	0.000101	CcSEcCtD
Tacrolimus—Vomiting—Epirubicin—pancreatic cancer	2.52e-05	9.79e-05	CcSEcCtD
Tacrolimus—Diarrhoea—Doxorubicin—pancreatic cancer	2.51e-05	9.75e-05	CcSEcCtD
Tacrolimus—Rash—Epirubicin—pancreatic cancer	2.5e-05	9.71e-05	CcSEcCtD
Tacrolimus—Dermatitis—Epirubicin—pancreatic cancer	2.5e-05	9.7e-05	CcSEcCtD
Tacrolimus—Headache—Epirubicin—pancreatic cancer	2.49e-05	9.65e-05	CcSEcCtD
Tacrolimus—Dizziness—Doxorubicin—pancreatic cancer	2.43e-05	9.42e-05	CcSEcCtD
Tacrolimus—Nausea—Epirubicin—pancreatic cancer	2.36e-05	9.15e-05	CcSEcCtD
Tacrolimus—Vomiting—Doxorubicin—pancreatic cancer	2.34e-05	9.06e-05	CcSEcCtD
Tacrolimus—Rash—Doxorubicin—pancreatic cancer	2.32e-05	8.98e-05	CcSEcCtD
Tacrolimus—Dermatitis—Doxorubicin—pancreatic cancer	2.31e-05	8.98e-05	CcSEcCtD
Tacrolimus—Headache—Doxorubicin—pancreatic cancer	2.3e-05	8.93e-05	CcSEcCtD
Tacrolimus—Nausea—Doxorubicin—pancreatic cancer	2.18e-05	8.46e-05	CcSEcCtD
Tacrolimus—CYP3A5—Metabolism—GLP1R—pancreatic cancer	1.69e-05	0.000137	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—PIK3CA—pancreatic cancer	1.69e-05	0.000137	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—pancreatic cancer	1.69e-05	0.000137	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—DPYD—pancreatic cancer	1.66e-05	0.000135	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—SRC—pancreatic cancer	1.66e-05	0.000135	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—PLAU—pancreatic cancer	1.66e-05	0.000135	CbGpPWpGaD
Tacrolimus—MTOR—Disease—HIF1A—pancreatic cancer	1.65e-05	0.000134	CbGpPWpGaD
Tacrolimus—MTOR—Disease—TSC2—pancreatic cancer	1.65e-05	0.000134	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CASP3—pancreatic cancer	1.65e-05	0.000134	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—AGTR1—pancreatic cancer	1.64e-05	0.000133	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—NFKBIA—pancreatic cancer	1.63e-05	0.000132	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—GCG—pancreatic cancer	1.62e-05	0.000132	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—STK11—pancreatic cancer	1.61e-05	0.000131	CbGpPWpGaD
Tacrolimus—MTOR—Disease—APOE—pancreatic cancer	1.61e-05	0.000131	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CCND1—pancreatic cancer	1.6e-05	0.00013	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—NRAS—pancreatic cancer	1.6e-05	0.00013	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—SRC—pancreatic cancer	1.6e-05	0.00013	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PIK3CD—pancreatic cancer	1.59e-05	0.00013	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—SRC—pancreatic cancer	1.59e-05	0.000129	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—CTNNB1—pancreatic cancer	1.59e-05	0.000129	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—TYMP—pancreatic cancer	1.58e-05	0.000129	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—SLC2A2—pancreatic cancer	1.58e-05	0.000128	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—TGFB1—pancreatic cancer	1.57e-05	0.000128	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—HRAS—pancreatic cancer	1.56e-05	0.000127	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—PIK3CA—pancreatic cancer	1.56e-05	0.000127	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—EGF—pancreatic cancer	1.56e-05	0.000127	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—MMP9—pancreatic cancer	1.56e-05	0.000127	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—pancreatic cancer	1.55e-05	0.000126	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatic cancer	1.55e-05	0.000126	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—PTEN—pancreatic cancer	1.55e-05	0.000126	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—NRAS—pancreatic cancer	1.54e-05	0.000125	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—STAT3—pancreatic cancer	1.53e-05	0.000125	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—NRAS—pancreatic cancer	1.53e-05	0.000124	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—STK11—pancreatic cancer	1.52e-05	0.000124	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—pancreatic cancer	1.52e-05	0.000123	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—AKT1—pancreatic cancer	1.51e-05	0.000123	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—APOE—pancreatic cancer	1.49e-05	0.000121	CbGpPWpGaD
Tacrolimus—MTOR—Disease—NOTCH1—pancreatic cancer	1.49e-05	0.000121	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—PIK3CG—pancreatic cancer	1.48e-05	0.00012	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—EGF—pancreatic cancer	1.46e-05	0.000119	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—EGFR—pancreatic cancer	1.46e-05	0.000118	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GLP1R—pancreatic cancer	1.46e-05	0.000118	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CDH1—pancreatic cancer	1.45e-05	0.000118	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	1.45e-05	0.000118	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—HRAS—pancreatic cancer	1.44e-05	0.000117	CbGpPWpGaD
Tacrolimus—MTOR—Disease—EGF—pancreatic cancer	1.44e-05	0.000117	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—SRC—pancreatic cancer	1.44e-05	0.000117	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	1.44e-05	0.000117	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—DPYD—pancreatic cancer	1.43e-05	0.000116	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—MYC—pancreatic cancer	1.42e-05	0.000116	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—TGFB1—pancreatic cancer	1.42e-05	0.000115	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SMAD4—pancreatic cancer	1.41e-05	0.000115	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—EGFR—pancreatic cancer	1.4e-05	0.000114	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—VEGFA—pancreatic cancer	1.4e-05	0.000114	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—EGFR—pancreatic cancer	1.39e-05	0.000113	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PIK3CB—pancreatic cancer	1.39e-05	0.000113	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PIK3CD—pancreatic cancer	1.39e-05	0.000113	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—STAT3—pancreatic cancer	1.38e-05	0.000113	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—NRAS—pancreatic cancer	1.38e-05	0.000112	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—HES1—pancreatic cancer	1.38e-05	0.000112	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—AKT1—pancreatic cancer	1.38e-05	0.000112	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—KRAS—pancreatic cancer	1.38e-05	0.000112	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—SLC2A2—pancreatic cancer	1.36e-05	0.00011	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PIK3CG—pancreatic cancer	1.35e-05	0.000109	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—PIK3CA—pancreatic cancer	1.34e-05	0.000109	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CXCL8—pancreatic cancer	1.33e-05	0.000108	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—KRAS—pancreatic cancer	1.32e-05	0.000107	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	1.32e-05	0.000107	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—KRAS—pancreatic cancer	1.32e-05	0.000107	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—TYMS—pancreatic cancer	1.31e-05	0.000107	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—PIK3CD—pancreatic cancer	1.3e-05	0.000106	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PPARG—pancreatic cancer	1.3e-05	0.000106	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PRSS1—pancreatic cancer	1.29e-05	0.000105	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—MYC—pancreatic cancer	1.29e-05	0.000105	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TGFB1—pancreatic cancer	1.28e-05	0.000104	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PIK3CD—pancreatic cancer	1.28e-05	0.000104	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CASP3—pancreatic cancer	1.28e-05	0.000104	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GLP1R—pancreatic cancer	1.28e-05	0.000104	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	1.28e-05	0.000104	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—AKT1—pancreatic cancer	1.27e-05	0.000104	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—PIK3CA—pancreatic cancer	1.26e-05	0.000103	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—EGFR—pancreatic cancer	1.26e-05	0.000102	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—DPYD—pancreatic cancer	1.26e-05	0.000102	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CCND1—pancreatic cancer	1.24e-05	0.000101	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—CTNNB1—pancreatic cancer	1.23e-05	0.0001	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—CD44—pancreatic cancer	1.22e-05	9.93e-05	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—PIK3CA—pancreatic cancer	1.21e-05	9.87e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TERT—pancreatic cancer	1.21e-05	9.83e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—PIK3CA—pancreatic cancer	1.21e-05	9.83e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PIK3CB—pancreatic cancer	1.21e-05	9.82e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MMP9—pancreatic cancer	1.21e-05	9.81e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PTEN—pancreatic cancer	1.2e-05	9.75e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—SLC2A2—pancreatic cancer	1.19e-05	9.68e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—KRAS—pancreatic cancer	1.19e-05	9.66e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PIK3CD—pancreatic cancer	1.18e-05	9.61e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—GCG—pancreatic cancer	1.17e-05	9.52e-05	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—HRAS—pancreatic cancer	1.17e-05	9.51e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—HIF1A—pancreatic cancer	1.16e-05	9.4e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TSC2—pancreatic cancer	1.15e-05	9.38e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—PIK3CB—pancreatic cancer	1.13e-05	9.2e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—APOE—pancreatic cancer	1.13e-05	9.18e-05	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—HRAS—pancreatic cancer	1.12e-05	9.13e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—HRAS—pancreatic cancer	1.12e-05	9.09e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PIK3CB—pancreatic cancer	1.12e-05	9.07e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—ARG2—pancreatic cancer	1.12e-05	9.07e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—SRC—pancreatic cancer	1.11e-05	9.05e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—KDR—pancreatic cancer	1.11e-05	8.99e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PTGS2—pancreatic cancer	1.11e-05	8.98e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—STK11—pancreatic cancer	1.1e-05	8.95e-05	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—AKT1—pancreatic cancer	1.09e-05	8.89e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—PIK3CA—pancreatic cancer	1.09e-05	8.87e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—VEGFA—pancreatic cancer	1.08e-05	8.81e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	1.08e-05	8.75e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—STAT3—pancreatic cancer	1.07e-05	8.72e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CTNNB1—pancreatic cancer	1.07e-05	8.71e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—NRAS—pancreatic cancer	1.07e-05	8.7e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—APOE—pancreatic cancer	1.07e-05	8.67e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TP53—pancreatic cancer	1.06e-05	8.59e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NFKBIA—pancreatic cancer	1.05e-05	8.55e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—CD44—pancreatic cancer	1.05e-05	8.55e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PTEN—pancreatic cancer	1.04e-05	8.49e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NOTCH1—pancreatic cancer	1.04e-05	8.47e-05	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—AKT1—pancreatic cancer	1.03e-05	8.4e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PIK3CB—pancreatic cancer	1.03e-05	8.38e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PTGS2—pancreatic cancer	1.02e-05	8.3e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3CG—pancreatic cancer	1.02e-05	8.29e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—HRAS—pancreatic cancer	1.01e-05	8.21e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—GCG—pancreatic cancer	1.01e-05	8.2e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—EGF—pancreatic cancer	1.01e-05	8.19e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MYC—pancreatic cancer	9.98e-06	8.11e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TGFB1—pancreatic cancer	9.95e-06	8.09e-05	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—AKT1—pancreatic cancer	9.92e-06	8.06e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CTNNB1—pancreatic cancer	9.89e-06	8.04e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—AKT1—pancreatic cancer	9.88e-06	8.03e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—EGFR—pancreatic cancer	9.76e-06	7.93e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—TYMP—pancreatic cancer	9.75e-06	7.92e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—SRC—pancreatic cancer	9.68e-06	7.87e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PTEN—pancreatic cancer	9.64e-06	7.83e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3CG—pancreatic cancer	9.62e-06	7.82e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—STK11—pancreatic cancer	9.49e-06	7.71e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—TYMS—pancreatic cancer	9.48e-06	7.7e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—STAT3—pancreatic cancer	9.34e-06	7.59e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—NRAS—pancreatic cancer	9.32e-06	7.57e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PPARG—pancreatic cancer	9.29e-06	7.55e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—CD44—pancreatic cancer	9.22e-06	7.5e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—KRAS—pancreatic cancer	9.22e-06	7.49e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—SRC—pancreatic cancer	9.07e-06	7.37e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3CD—pancreatic cancer	8.96e-06	7.28e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—SRC—pancreatic cancer	8.94e-06	7.27e-05	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—AKT1—pancreatic cancer	8.92e-06	7.25e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PTEN—pancreatic cancer	8.91e-06	7.24e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—GCG—pancreatic cancer	8.84e-06	7.19e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—VEGFA—pancreatic cancer	8.84e-06	7.18e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—NRAS—pancreatic cancer	8.73e-06	7.09e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—STAT3—pancreatic cancer	8.62e-06	7.01e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—NRAS—pancreatic cancer	8.6e-06	6.99e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—EGFR—pancreatic cancer	8.49e-06	6.9e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—PIK3CA—pancreatic cancer	8.47e-06	6.88e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3CD—pancreatic cancer	8.46e-06	6.88e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—STK11—pancreatic cancer	8.31e-06	6.76e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TP53—pancreatic cancer	8.19e-06	6.66e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—TYMS—pancreatic cancer	8.16e-06	6.63e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TGFB1—pancreatic cancer	8.11e-06	6.59e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—KRAS—pancreatic cancer	8.02e-06	6.52e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—MYC—pancreatic cancer	8.01e-06	6.51e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—TGFB1—pancreatic cancer	7.99e-06	6.49e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GLP1R—pancreatic cancer	7.86e-06	6.39e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—EGFR—pancreatic cancer	7.84e-06	6.37e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—HRAS—pancreatic cancer	7.83e-06	6.37e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3CB—pancreatic cancer	7.81e-06	6.35e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—DPYD—pancreatic cancer	7.73e-06	6.28e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—APOE—pancreatic cancer	7.71e-06	6.26e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—KRAS—pancreatic cancer	7.51e-06	6.11e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CXCL8—pancreatic cancer	7.51e-06	6.1e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—KRAS—pancreatic cancer	7.4e-06	6.02e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3CB—pancreatic cancer	7.37e-06	5.99e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—PIK3CA—pancreatic cancer	7.37e-06	5.99e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—SLC2A2—pancreatic cancer	7.34e-06	5.96e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PTGS2—pancreatic cancer	7.31e-06	5.94e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CASP3—pancreatic cancer	7.19e-06	5.84e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—TYMS—pancreatic cancer	7.15e-06	5.81e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CCND1—pancreatic cancer	6.99e-06	5.68e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3CG—pancreatic cancer	6.96e-06	5.65e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—CTNNB1—pancreatic cancer	6.93e-06	5.63e-05	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—AKT1—pancreatic cancer	6.92e-06	5.62e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—PIK3CA—pancreatic cancer	6.9e-06	5.61e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—HRAS—pancreatic cancer	6.82e-06	5.54e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—PIK3CA—pancreatic cancer	6.8e-06	5.53e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MMP9—pancreatic cancer	6.79e-06	5.52e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PTEN—pancreatic cancer	6.75e-06	5.49e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PPARG—pancreatic cancer	6.71e-06	5.46e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TP53—pancreatic cancer	6.68e-06	5.43e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—APOE—pancreatic cancer	6.64e-06	5.39e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—HRAS—pancreatic cancer	6.39e-06	5.19e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PTEN—pancreatic cancer	6.37e-06	5.18e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—HRAS—pancreatic cancer	6.29e-06	5.11e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism of lipids and lipoproteins—PIK3CA—pancreatic cancer	6.28e-06	5.11e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—SRC—pancreatic cancer	6.26e-06	5.09e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3CD—pancreatic cancer	6.12e-06	4.97e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—VEGFA—pancreatic cancer	6.1e-06	4.96e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—STAT3—pancreatic cancer	6.04e-06	4.91e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—NRAS—pancreatic cancer	6.02e-06	4.89e-05	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—AKT1—pancreatic cancer	6.02e-06	4.89e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3CG—pancreatic cancer	5.99e-06	4.87e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—APOE—pancreatic cancer	5.82e-06	4.73e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PPARG—pancreatic cancer	5.78e-06	4.7e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—CD44—pancreatic cancer	5.68e-06	4.62e-05	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—AKT1—pancreatic cancer	5.64e-06	4.58e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MYC—pancreatic cancer	5.61e-06	4.56e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TGFB1—pancreatic cancer	5.6e-06	4.55e-05	CbGpPWpGaD
Tacrolimus—MTOR—Disease—AKT1—pancreatic cancer	5.56e-06	4.51e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—EGFR—pancreatic cancer	5.49e-06	4.46e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—GCG—pancreatic cancer	5.45e-06	4.43e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3CB—pancreatic cancer	5.33e-06	4.33e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PTGS2—pancreatic cancer	5.28e-06	4.29e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3CD—pancreatic cancer	5.27e-06	4.28e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3CG—pancreatic cancer	5.25e-06	4.27e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—KRAS—pancreatic cancer	5.18e-06	4.21e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—STK11—pancreatic cancer	5.12e-06	4.16e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PPARG—pancreatic cancer	5.07e-06	4.12e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—PIK3CA—pancreatic cancer	4.76e-06	3.87e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3CD—pancreatic cancer	4.61e-06	3.75e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TP53—pancreatic cancer	4.61e-06	3.74e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PTEN—pancreatic cancer	4.61e-06	3.74e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3CB—pancreatic cancer	4.59e-06	3.73e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PTGS2—pancreatic cancer	4.55e-06	3.7e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—PIK3CA—pancreatic cancer	4.5e-06	3.65e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—TYMS—pancreatic cancer	4.41e-06	3.58e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—HRAS—pancreatic cancer	4.41e-06	3.58e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3CB—pancreatic cancer	4.02e-06	3.27e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PTGS2—pancreatic cancer	3.99e-06	3.24e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PTEN—pancreatic cancer	3.97e-06	3.22e-05	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—AKT1—pancreatic cancer	3.89e-06	3.16e-05	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—AKT1—pancreatic cancer	3.67e-06	2.98e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—APOE—pancreatic cancer	3.58e-06	2.91e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PTEN—pancreatic cancer	3.48e-06	2.82e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—PIK3CA—pancreatic cancer	3.25e-06	2.64e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3CG—pancreatic cancer	3.23e-06	2.63e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PPARG—pancreatic cancer	3.12e-06	2.54e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3CD—pancreatic cancer	2.84e-06	2.31e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—PIK3CA—pancreatic cancer	2.8e-06	2.27e-05	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—AKT1—pancreatic cancer	2.65e-06	2.16e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3CB—pancreatic cancer	2.48e-06	2.01e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PTGS2—pancreatic cancer	2.46e-06	2e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—PIK3CA—pancreatic cancer	2.45e-06	1.99e-05	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—AKT1—pancreatic cancer	2.29e-06	1.86e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PTEN—pancreatic cancer	2.14e-06	1.74e-05	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—AKT1—pancreatic cancer	2e-06	1.63e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—PIK3CA—pancreatic cancer	1.51e-06	1.23e-05	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—AKT1—pancreatic cancer	1.23e-06	1e-05	CbGpPWpGaD
